Maintain compliance with a Direct to Patient via Site drug shipment strategy

Case study

 
Home /

Supporting patients enrolled in clinical trials, and improving their participation experience, is a top priority for sponsors.

Developing a drug shipment strategy to introduce enhanced convenience to patients not only supports retention, by reducing a patient’s travel time, costs and number of visits to a clinical site, but delivers added value to sponsors through improved supply chain continuity and end to end temperature controlled compliance.

A Direct to Patient (DtP) via site strategy, where investigational products (IP) are dispatched from a depot to a clinical site before being dispensed by a pharmacist to the patient’s home, can open-up trials to a wider patient population. In doing so, it can accelerate a trial’s total duration, making new medications accessible to patients more quickly.

Download the case study to find out more.

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies